drugset / Trial / NCT00455494
Food-Effect Bioavailability Study of AQ-13, a Candidate Antimalarial
Phase 1
Completed
14 enrolled
Tulane University Health Sciences Center
Centers for Disease Control and Prevention · collab
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of this study is to test the safety of a 2100 mg dose of AQ-13, a new candidate antimalarial active against drug-resistant P. falciparum infection, and to determine the effect of a standard fatty meal on the absorption of the drug from the gut and its blood levels.
Timeline
- Start
- 2005-01
- Primary completion
- 2006-12
- Completion
- 2006-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AQ-13 | Small molecule | 700 mg | — |